Pentixapharm Holding AG (ETR:PTP) | WebDisclosure

Basculer en Français

10817	Companies
234430	Keywords
163287	Articles
125437	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

PRESS RELEASE

published on 10/06/2025 at 11:00, 10 months 4 days ago

Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
Pentixapharm presents new clinical findings on expanding CXCR4 radiopharmaceutical platform at EANM 2025, demonstrating potential in diagnosis and therapeutics in Primary Aldosteronism and bladder cancer

Pentixapharm CXCR4 Radiopharmaceutical EANM 2025 Clinical Findings
BRIEF

published on 09/26/2025 at 08:05, 10 months 14 days ago

Pentixapharm Advances PentixaTher in AML Trial

Clinical Trial Radiopharmaceuticals Acute Myeloid Leukemia PentixaTher CXCR4-targeting
BRIEF

published on 09/26/2025 at 08:05, 10 months 14 days ago

Pentixapharm fait progresser PentixaTher dans l'essai sur la LAM

Essai Clinique Produits Radiopharmaceutiques Ciblage CXCR4 Leucémie Myéloïde Aiguë PentixaTher
PRESS RELEASE

published on 09/26/2025 at 08:00, 10 months 14 days ago

Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial
Pentixapharm advances PentixaTher to fourth dose level in AML trial, reinforcing safety profile and potential clinical efficacy for CXCR4-targeted radiotherapeutic in high unmet need indication

Pentixapharm CXCR4 Acute Myeloid Leukemia Radiotherapeutic PentixaTher
BRIEF

published on 05/27/2025 at 09:48, 1 year 2 months ago

Pentixapharm Unveils New Clinical Development Strategy

Oncology Pentixapharm CXCR4 Trials Theranostic Strategy Hematologic Malignancies
BRIEF

published on 05/27/2025 at 09:48, 1 year 2 months ago

Pentixapharm dévoile une nouvelle stratégie de développement clinique

Oncologie Pentixapharm Essais CXCR4 Stratégie Théranostique Hémopathies Malignes
PRESS RELEASE

published on 05/27/2025 at 09:43, 1 year 2 months ago

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
Pentixapharm outlines new clinical development strategy focusing on CXCR4 therapeutic and diagnostic oncology programs, discontinuing PTF301 trial in MZL, preparing new trials in hematologic malignancies and Bladder Cancer

Pentixapharm CXCR4 Oncology Programs Clinical Development Strategy Theranostic Precision
BRIEF

published on 04/25/2025 at 15:44, 1 year 3 months ago

Pentixapharm to Showcase Innovative Antibody GT-008 at AACR 2025

Cancer Therapy Pentixapharm GT-008 Antibody Glycan-Dependent CD24 Targeting
BRIEF

published on 04/25/2025 at 15:44, 1 year 3 months ago

Pentixapharm présentera son anticorps innovant GT-008 à l'AACR 2025

Thérapie Contre Le Cancer Pentixapharm Anticorps GT-008 Glycane-dépendant Ciblage CD24
PRESS RELEASE

published on 04/25/2025 at 15:39, 1 year 3 months ago

Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
Pentixapharm to present novel CD24 antibody GT-008 for solid tumors at AACR 2025, showcasing glycan-dependent mechanism for targeted therapy

Solid Tumors Pentixapharm AACR 2025 GT-008 CD24 Antibody

Accesswire

Published on 08/11/2026 at 00:40, 13 minutes ago

CORRECTION FROM SOURCE: Fermi Announces Binding Lease Agreement with TensorWave
Published on 08/11/2026 at 00:25, 28 minutes ago

Empress Reports 2026 Second Quarter Financial Results
Published on 08/10/2026 at 23:35, 1 hour 18 minutes ago

NioCorp Project to Expand Production to 8 Made-in-USA Critical Minerals Over a 40-Year Mine Life with an Estimated $4.1 Billion Pre-Tax NPV8%
Published on 08/10/2026 at 23:30, 1 hour 23 minutes ago

Condor and Element79 Agree on Restructured Terms for Lucero Project
Published on 08/10/2026 at 23:25, 1 hour 28 minutes ago

Ur-Energy Reports Second Quarter 2026 Results

View all ACCESSWIRE

EQS Group

Published on 08/10/2026 at 22:15, 2 hours 38 minutes ago

Amrize Files Form 10-Q for Second Quarter 2026
Published on 08/10/2026 at 22:05, 2 hours 48 minutes ago

Immunic Appoints Elena Ridloff to Board of Directors
Published on 08/10/2026 at 20:24, 4 hours 29 minutes ago

EQS-Adhoc: PNE AG updates on ongoing sales process
Published on 08/10/2026 at 19:35, 5 hours 18 minutes ago

Kontron AG: All conditions of the mandatory tender offer of Ennoconn Corporation are met – Settlement will take place shortly
Published on 08/10/2026 at 19:00, 5 hours 53 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026

Les Echos

Published on 08/10/2026 at 18:00, 6 hours 53 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 6 hours 53 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 7 hours 8 minutes ago

Weekly share buyback
Published on 08/10/2026 at 17:45, 7 hours 8 minutes ago

Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 12 hours 59 minutes ago

GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026

View all LES ECHOS COMFI WIRE